Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.

Wiseman DH, Small HF, Wilks DP, Waddell ID, Dennis MW, Ogilvie DJ, Somervaille TC.

Br J Haematol. 2014 Jul;166(1):145-8. doi: 10.1111/bjh.12826. Epub 2014 Mar 10. No abstract available.

PMID:
24606602
2.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillot D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S.

J Clin Oncol. 2014 Feb 1;32(4):297-305. doi: 10.1200/JCO.2013.50.2047. Epub 2013 Dec 16.

PMID:
24344214
3.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 May 10;28(14):2356-64. doi: 10.1200/JCO.2009.27.6899. Epub 2010 Apr 5.

PMID:
20368538
4.

Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.

Wang XW, Boisselier B, Rossetto M, Marie Y, Idbaih A, Mokhtari K, Gousias K, Hoang-Xuan K, Delattre JY, Simon M, Labussière M, Sanson M.

Cancer. 2013 Feb 15;119(4):806-13. doi: 10.1002/cncr.27798. Epub 2012 Nov 26.

5.

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.

Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC.

Leuk Lymphoma. 2013 Feb;54(2):408-10. doi: 10.3109/10428194.2012.701009. Epub 2012 Jul 9. No abstract available.

6.

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.

Balss J, Thiede C, Bochtler T, Okun JG, Saadati M, Benner A, Pusch S, Ehninger G, Schaich M, Ho AD, von Deimling A, Krämer A, Heilig CE.

Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19.

PMID:
26582645
7.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M.

Blood. 2013 Jun 13;121(24):4917-24. doi: 10.1182/blood-2013-03-493197. Epub 2013 May 2.

8.

Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.

Wiseman DH, Struys EA, Wilks DP, Clark CI, Dennis MW, Jansen EE, Salomons GS, Somervaille TC.

Leukemia. 2015 Dec;29(12):2421-3. doi: 10.1038/leu.2015.151. Epub 2015 Jun 19. No abstract available.

PMID:
26088953
9.

Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.

Wang JH, Chen WL, Li JM, Wu SF, Chen TL, Zhu YM, Zhang WN, Li Y, Qiu YP, Zhao AH, Mi JQ, Jin J, Wang YG, Ma QL, Huang H, Wu DP, Wang QR, Li Y, Yan XJ, Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Jia W, Shen Y, Chen Z, Chen SJ.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17017-22. doi: 10.1073/pnas.1315558110. Epub 2013 Sep 30.

10.

Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.

Rakheja D, Fuda F, Vandergriff T, Boriack R, Medeiros BC, Frankel AE, Chen W.

Hum Pathol. 2015 Feb;46(2):322-6. doi: 10.1016/j.humpath.2014.10.013. Epub 2014 Nov 4.

PMID:
25481493
11.

Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.

Sellner L, Capper D, Meyer J, Langhans CD, Hartog CM, Pfeifer H, Serve H, Ho AD, Okun JG, Krämer A, Von Deimling A.

Eur J Haematol. 2010 Nov;85(5):457-9. doi: 10.1111/j.1600-0609.2010.01505.x. No abstract available.

PMID:
20659156
12.

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.

Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S.

Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26.

13.

Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR.

Oncologist. 2014 Jun;19(6):602-7. doi: 10.1634/theoncologist.2013-0417. Epub 2014 Apr 23.

14.

Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.

Balss J, Pusch S, Beck AC, Herold-Mende C, Krämer A, Thiede C, Buckel W, Langhans CD, Okun JG, von Deimling A.

Acta Neuropathol. 2012 Dec;124(6):883-91. doi: 10.1007/s00401-012-1060-y. Epub 2012 Nov 2.

PMID:
23117877
15.

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.

Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, Zwaan CM, de Haas V, Creutzig U, Klusmann JH, Krauter J, Heuser M, Ganser A, Reinhardt D, Thiede C.

Leukemia. 2011 Nov;25(11):1704-10. doi: 10.1038/leu.2011.142. Epub 2011 Jun 7.

PMID:
21647152
16.

2-Hydroxyglutarate is not a metabolite; D-2-hydroxyglutarate and L-2-hydroxyglutarate are!

Struys EA.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4939. doi: 10.1073/pnas.1318777110. Epub 2013 Dec 6. No abstract available.

17.

The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia.

McGehee E, Rakheja D, Oliver D, Chen W, Boriack R, Collins RH Jr.

Br J Haematol. 2016 Apr;173(2):323-6. doi: 10.1111/bjh.13598. Epub 2015 Jul 20. No abstract available.

PMID:
26195003
18.

Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.

Rakheja D, Mitui M, Boriack RL, DeBerardinis RJ.

Pediatr Blood Cancer. 2011 Mar;56(3):379-83. doi: 10.1002/pbc.22697. Epub 2010 Nov 22.

PMID:
21225914
19.

Metabolic syndromes and malignant transformation: where the twain shall meet.

Bhagwat N, Levine RL.

Sci Transl Med. 2010 Oct 20;2(54):54ps50. doi: 10.1126/scitranslmed.3001669.

PMID:
20962328
20.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

Supplemental Content

Support Center